ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,084.61
-0.26%
Dow Jones
42,840.26
1.18%
Gold vs US Dollar
2,623.175
0.00%
Brent Oil
72.72
0.00%
Bitcoin
96,952.37
-0.26%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. IceCure Medical Ltd (ICCM)

  7. IceCure Medical Ltd (ICCM) News

IceCure Medical (ICCM)

IceCure Medical Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ICCM
DateTimeSourceHeadlineSymbolCompany
16/12/202413:30PR Newswire (US)Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual MeetingNASDAQ:ICCMIceCure Medical Ltd
05/12/202413:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
05/12/202413:30PR Newswire (US)IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study ResultsNASDAQ:ICCMIceCure Medical Ltd
26/11/202413:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
26/11/202413:30PR Newswire (US)IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® CryoablationNASDAQ:ICCMIceCure Medical Ltd
25/11/202413:50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
25/11/202413:30PR Newswire (US)IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent OfficeNASDAQ:ICCMIceCure Medical Ltd
20/11/202413:30PR Newswire (US)IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024NASDAQ:ICCMIceCure Medical Ltd
19/11/202413:30PR Newswire (US)IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of HealthNASDAQ:ICCMIceCure Medical Ltd
15/11/202402:38Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ICCMIceCure Medical Ltd
08/11/202415:05Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:ICCMIceCure Medical Ltd
08/11/202412:08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
08/11/202412:00PR Newswire (US)FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast CancerNASDAQ:ICCMIceCure Medical Ltd
05/11/202421:41Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:ICCMIceCure Medical Ltd
29/10/202412:30PR Newswire (US)Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from StakeholdersNASDAQ:ICCMIceCure Medical Ltd
21/10/202412:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
21/10/202412:30PR Newswire (US)IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation SystemNASDAQ:ICCMIceCure Medical Ltd
15/10/202420:22Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:ICCMIceCure Medical Ltd
07/10/202412:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
07/10/202412:15PR Newswire (US)IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging ConferenceNASDAQ:ICCMIceCure Medical Ltd
24/09/202412:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
24/09/202412:15PR Newswire (US)IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free RateNASDAQ:ICCMIceCure Medical Ltd
16/09/202412:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
16/09/202412:00PR Newswire (US)Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft TissuesNASDAQ:ICCMIceCure Medical Ltd
12/09/202412:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
12/09/202412:00PR Newswire (US)IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024NASDAQ:ICCMIceCure Medical Ltd
04/09/202412:30PR Newswire (US)IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets ConferencesNASDAQ:ICCMIceCure Medical Ltd
28/08/202412:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
28/08/202412:30PR Newswire (US)USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation TechnologiesNASDAQ:ICCMIceCure Medical Ltd
20/08/202413:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
 Showing the most relevant articles for your search:NASDAQ:ICCM

Your Recent History

LSE
POS
Plexus
LSE
SYME
Supply@me Capital
LSE
MIN
Minoan
LSE
GKP
Gulf Keystone Petroleum
LSE
AAZ
Anglo Asian Mining
LSE
VAST
Vast Resources
LSE
INSG
Insig Ai
LSE
BARC
Barclays
LSE
THUS
Thus
LSE
ITV
Itv
LSE
EME
Empyrean Energy
LSE
OCDO
Ocado
LSE
VRS
Versarien
LSE
SRSP
Sirius Petroleum
LSE
ITH
Ithaca Energy
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads